

Inotuzumab Biosimilar - Research Grade

Product Code: ICH5247

More Information

Species Reactivity: Human

Target: CD22

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Inotuzumab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse CD22 \(Cy34.1\) In Vivo Antibody - Low Endotoxin \(ICH1181\)](#), [Anti-Mouse CD22 \(MB22-11\) In Vivo Antibody - Low Endotoxin \(ICH1216\)](#), [Pinatuzumab Biosimilar - Research Grade \(ICH5093\)](#), [Epratuzumab Biosimilar - Research Grade \(ICH5194\)](#), [Bectumomab Biosimilar - Research Grade \(ICH5379\)](#), [Mozistobart Biosimilar - Research Grade \(ICH5693\)](#), [Suciraslimab Biosimilar - Research Grade \(ICH5884\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P20273

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of inotuzumab, supplied for research use only. It is built around CD22 (Siglec-2), the B-cell surface antigen that the originator antibody engages, and reproduces the human IgG4-kappa framework so investigators can study antigen recognition and antibody behaviour in defined systems. It is not the clinical drug and, importantly, is not conjugated to a payload; the marketed originator is delivered as an antibody-drug conjugate, so this bare analog is

intended as a research tool and a starting point for conjugation or ADC-development chemistry rather than as a therapeutic. Typical applications include CD22-binding and specificity assays, use as an isotype-matched or target-specific reference standard, flow-cytometry and imaging staining of CD22-positive cells, and preclinical characterisation work. Material is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening campaigns and reproducible in-vitro studies. Not for human or veterinary use. CD22 (Siglec-2) is a type I transmembrane sialic-acid-binding immunoglobulin-like lectin restricted almost entirely to the B-cell lineage. Its extracellular region carries multiple Ig-like domains, with the N-terminal V-set domain recognising alpha-2,6-linked sialic acid on glycoproteins, mediating both homotypic and heterotypic interactions. CD22 functions as an inhibitory co-receptor of the B-cell receptor: antigen engagement drives phosphorylation of cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which recruit the phosphatase SHP-1 to dampen BCR signalling and set B-cell activation thresholds. It also contributes to B-cell survival, adhesion and homing to bone marrow. Because CD22 is expressed across most B-cell malignancies yet absent from stem cells, and because it internalises rapidly on antibody binding, it is an established target for antibody and antibody-drug-conjugate approaches in B-cell disease.

Other names: CAT-8015, GCR-8015, HA22, (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14

Specificity: Detects human CD22

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks